Follow
Nasser Altorki
Nasser Altorki
Profess of surgery
Verified email at med.cornell.edu
Title
Cited by
Cited by
Year
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
RN Kaplan, RD Riba, S Zacharoulis, AH Bramley, L Vincent, C Costa, ...
Nature 438 (7069), 820-827, 2005
37912005
Early Lung Cancer Action Project: overall design and findings from baseline screening
CI Henschke, DI McCauley, DF Yankelevitz, DP Naidich, G McGuinness, ...
The Lancet 354 (9173), 99-105, 1999
33181999
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
KR Fischer, A Durrans, S Lee, J Sheng, F Li, STC Wong, H Choi, ...
Nature 527 (7579), 472-476, 2015
19092015
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
S Gnjatic, D Atanackovic, E Jäger, M Matsuo, A Selvakumar, NK Altorki, ...
Proceedings of the National Academy of Sciences 100 (15), 8862-8867, 2003
9802003
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
E Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko, O Goloborodko, ...
The Lancet 398 (10308), 1344-1357, 2021
9342021
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database
S Paul, NK Altorki, S Sheng, PC Lee, DH Harpole, MW Onaitis, BM Stiles, ...
The Journal of thoracic and cardiovascular surgery 139 (2), 366-378, 2010
9072010
The lung microenvironment: an important regulator of tumour growth and metastasis
NK Altorki, GJ Markowitz, D Gao, JL Port, A Saxena, B Stiles, T McGraw, ...
Nature Reviews Cancer 19 (1), 9-31, 2019
8382019
TOX is a critical regulator of tumour-specific T cell differentiation
AC Scott, F Dündar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ...
Nature 571 (7764), 270-274, 2019
8302019
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
AJ Dannenberg, NK Altorki, JO Boyle, C Dang, LR Howe, BB Weksler, ...
The lancet oncology 2 (9), 544-551, 2001
8172001
Early Lung Cancer Action Project: initial findings on repeat screening
CI Henschke, DP Naidich, DF Yankelevitz, G McGuinness, DI McCauley, ...
Cancer 92 (1), 153-159, 2001
7002001
The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection
CG Peyre, JA Hagen, SR DeMeester, NK Altorki, E Ancona, SM Griffin, ...
Annals of surgery 248 (4), 549-556, 2008
6682008
Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues
AA Jungbluth, YT Chen, E Stockert, KJ Busam, D Kolb, K Iversen, ...
International Journal of Cancer 92 (6), 856-860, 2001
6642001
Inhibition of cyclooxygenase-2 gene expression by p53
K Subbaramaiah, N Altorki, WJ Chung, JR Mestre, A Sampat, ...
Journal of Biological Chemistry 274 (16), 10911-10915, 1999
5201999
Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus
N Altorki, M Kent, C Ferrara, J Port
Annals of surgery 236 (2), 177-183, 2002
5182002
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial
K Kelly, NK Altorki, WEE Eberhardt, MER O'Brien, DR Spigel, L Crinò, ...
Journal of Clinical Oncology 33 (34), 4007-4014, 2015
4922015
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival
EA Mathé, GH Nguyen, ED Bowman, Y Zhao, A Budhu, AJ Schetter, ...
Clinical cancer research 15 (19), 6192-6200, 2009
4802009
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind …
JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, ...
The lancet oncology 17 (6), 822-835, 2016
4742016
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non–small cell lung cancer
AO Gure, R Chua, B Williamson, M Gonen, CA Ferrera, S Gnjatic, G Ritter, ...
Clinical Cancer Research 11 (22), 8055-8062, 2005
4592005
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Z Yao, S Fenoglio, DC Gao, M Camiolo, B Stiles, T Lindsted, ...
Proceedings of the National Academy of Sciences 107 (35), 15535-15540, 2010
4342010
Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestinal epithelial cells
F Zhang, NK Altorki, JR Mestre, K Subbaramaiah, AJ Dannenberg
Carcinogenesis 20 (3), 445-451, 1999
4081999
The system can't perform the operation now. Try again later.
Articles 1–20